IRWD vs. INVA, OPK, MNKD, DVAX, CYRX, LGND, IGMS, KURA, LXRX, and VSTM
Should you be buying Ironwood Pharmaceuticals stock or one of its competitors? The main competitors of Ironwood Pharmaceuticals include Innoviva (INVA), OPKO Health (OPK), MannKind (MNKD), Dynavax Technologies (DVAX), Cryoport (CYRX), Ligand Pharmaceuticals (LGND), IGM Biosciences (IGMS), Kura Oncology (KURA), Lexicon Pharmaceuticals (LXRX), and Verastem (VSTM). These companies are all part of the "pharmaceutical preparations" industry.
Ironwood Pharmaceuticals (NASDAQ:IRWD) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations, community ranking and media sentiment.
Innoviva has lower revenue, but higher earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.
Ironwood Pharmaceuticals received 209 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 61.09% of users gave Ironwood Pharmaceuticals an outperform vote while only 57.28% of users gave Innoviva an outperform vote.
Innoviva has a net margin of 58.21% compared to Ironwood Pharmaceuticals' net margin of -254.41%. Innoviva's return on equity of 28.94% beat Ironwood Pharmaceuticals' return on equity.
In the previous week, Ironwood Pharmaceuticals had 15 more articles in the media than Innoviva. MarketBeat recorded 20 mentions for Ironwood Pharmaceuticals and 5 mentions for Innoviva. Innoviva's average media sentiment score of 1.75 beat Ironwood Pharmaceuticals' score of 0.15 indicating that Innoviva is being referred to more favorably in the news media.
Ironwood Pharmaceuticals presently has a consensus target price of $18.40, indicating a potential upside of 212.93%. Given Ironwood Pharmaceuticals' higher possible upside, equities research analysts plainly believe Ironwood Pharmaceuticals is more favorable than Innoviva.
Ironwood Pharmaceuticals has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.
99.1% of Innoviva shares are held by institutional investors. 12.9% of Ironwood Pharmaceuticals shares are held by company insiders. Comparatively, 1.4% of Innoviva shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Ironwood Pharmaceuticals and Innoviva tied by winning 8 of the 16 factors compared between the two stocks.
Get Ironwood Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IRWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ironwood Pharmaceuticals Competitors List
Related Companies and Tools
